Eli Lilly’s ongoing technology evaluation agreement with Peptron, originally signed in October 2024 and extended through October 7, 2026, for additional in-vivo studies on SmartDepot microsphere formulations, remains the dominant factor keeping the implied probability of a commercial license by the deadline at just 12.5%. The non-binding pact grants Lilly only internal R&D rights to apply the long-acting injectable platform—using ultrasonic spray drying for uniform PLGA microspheres—to peptide candidates like GLP-1 agonists, with easy termination rights and no commitment to a full technology transfer or commercialization deal. Recent expansions of the collaboration into CNS applications have not produced binding announcements, while Lilly’s parallel work with alternative delivery systems like Camurus FluidCrystal underscores optionality. With one month left and no credible signals of an imminent commercial agreement, traders see resolution to “No” as highly likely.
Tóm tắt AI thử nghiệm tham chiếu dữ liệu Polymarket. Đây không phải tư vấn giao dịch và không ảnh hưởng đến cách thị trường này được giải quyết. · Cập nhật13% khả năng
$11,314 KL.
$11,314 KL.
Oct 6, 2026
13% khả năng
$11,314 KL.
$11,314 KL.
Oct 6, 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s ongoing technology evaluation agreement with Peptron, originally signed in October 2024 and extended through October 7, 2026, for additional in-vivo studies on SmartDepot microsphere formulations, remains the dominant factor keeping the implied probability of a commercial license by the deadline at just 12.5%. The non-binding pact grants Lilly only internal R&D rights to apply the long-acting injectable platform—using ultrasonic spray drying for uniform PLGA microspheres—to peptide candidates like GLP-1 agonists, with easy termination rights and no commitment to a full technology transfer or commercialization deal. Recent expansions of the collaboration into CNS applications have not produced binding announcements, while Lilly’s parallel work with alternative delivery systems like Camurus FluidCrystal underscores optionality. With one month left and no credible signals of an imminent commercial agreement, traders see resolution to “No” as highly likely.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Thị trường mở: May 5, 2026, 8:02 PM ET
Khối lượng
$11,314Ngày kết thúc
Oct 7, 2026Thị trường mở
May 5, 2026, 8:02 PM ETNgười giải quyết
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s ongoing technology evaluation agreement with Peptron, originally signed in October 2024 and extended through October 7, 2026, for additional in-vivo studies on SmartDepot microsphere formulations, remains the dominant factor keeping the implied probability of a commercial license by the deadline at just 12.5%. The non-binding pact grants Lilly only internal R&D rights to apply the long-acting injectable platform—using ultrasonic spray drying for uniform PLGA microspheres—to peptide candidates like GLP-1 agonists, with easy termination rights and no commitment to a full technology transfer or commercialization deal. Recent expansions of the collaboration into CNS applications have not produced binding announcements, while Lilly’s parallel work with alternative delivery systems like Camurus FluidCrystal underscores optionality. With one month left and no credible signals of an imminent commercial agreement, traders see resolution to “No” as highly likely.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Khối lượng
$11,314Ngày kết thúc
Oct 7, 2026Thị trường mở
May 5, 2026, 8:02 PM ETNgười giải quyết
0x65070BE91...Eli Lilly’s ongoing technology evaluation agreement with Peptron, originally signed in October 2024 and extended through October 7, 2026, for additional in-vivo studies on SmartDepot microsphere formulations, remains the dominant factor keeping the implied probability of a commercial license by the deadline at just 12.5%. The non-binding pact grants Lilly only internal R&D rights to apply the long-acting injectable platform—using ultrasonic spray drying for uniform PLGA microspheres—to peptide candidates like GLP-1 agonists, with easy termination rights and no commitment to a full technology transfer or commercialization deal. Recent expansions of the collaboration into CNS applications have not produced binding announcements, while Lilly’s parallel work with alternative delivery systems like Camurus FluidCrystal underscores optionality. With one month left and no credible signals of an imminent commercial agreement, traders see resolution to “No” as highly likely.
Tóm tắt AI thử nghiệm tham chiếu dữ liệu Polymarket. Đây không phải tư vấn giao dịch và không ảnh hưởng đến cách thị trường này được giải quyết. · Cập nhật
Cẩn thận với liên kết bên ngoài.
Cẩn thận với liên kết bên ngoài.
Câu hỏi thường gặp